BioWorld

April 10, 2009

View Archived Issues

Cardiome Gets Much-Needed Deal in $800M Merck Alliance

Shares of Cardiome Pharma Corp. shot up 25 percent after it scored a crucial partnership for its late-stage atrial fibrillation drug, vernakalant. (BioWorld Today) Read More

After PML Cases, Genentech Takes Raptiva off the Market

Read More

Mechanistics Guide Drug for Advanced Prostate Cancer

Read More

Celldex Dusting Off Program Idled Years Ago by Amgen

Read More

Clinic Roundup

Read More

Other News To Note

Read More

Financings Roundup

Read More